Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Oncologists Specializing in Hematologic Malignancies in the U.S.

Articles with lock require a subscription to GLG News | Request a free trial
Taral PatelFebruary 19, 2008
Avastin In Breast cancer
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
New data with low and high dose of Avastin with Taxoter
Taral PatelFebruary 19, 2008
improve Overall survival in prostate cancer
Analysis of: Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
Author: Taral Patel, Oncologist, Mid Ohio Oncology Hematology Inc.
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients'...
February 18, 2008
Sutent's " Cardiac Worries" grow: Nexavar and Torisel to benefit
Analysis of: Kidney Cancer Drug Linked to Higher Rate of Heart Problems | www.washingtonpost.com
Author: GLG Expert Contributor
Yet another study, although small, report 15 5 incidence of cardiac abnormalities in patients receiving Pfizer's Sutent. The abnormalities persist and are serious in patients with previous history of cardiac disease. Sutent is an efficacious drug, but it has alternative options ( Nexavar and Torisel...
February 15, 2008
Avastin for recurrent breast cncer: improvement in time to progression may be enough for FDA approval!!!
Analysis of: In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
Author: GLG Expert Contributor
A recent trial showed that Genentech's Avastin when added to Docotaxel , increased time to progression in patients with recurrent breast cancer. This trial confirms results of a previous study and is reported to have better safety profile. Although survival data are still pending, the efficacy results...
February 13, 2008
Fears of safety and fears of a black box warning.
Analysis of: FDA Issues Warning About Botox Deaths | www.pharmalot.com
Author: GLG Expert Contributor
Is Botox as safe as we have imagined it to be? The implications of an impending possible black box warning on the cosmetic and medical use of Botox in dermatology.
February 7, 2008
Oral Toptecan: Efficay with narrow market and limited use
Analysis of: GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer | www.pipelinereview.com
Author: GLG Expert Contributor
GSK's oral topotecan was favorably reviewed in Europe for treatment of recurrent small cell cancer. IV topotecan is used in ovarian cancer , sarcomas, an rarely in hematological malignancies. The indication is quite narrow and oral use is complicated by lack of re-imbursement and poor patient...
February 7, 2008
Sutent for NSCLC: Role for combination therapy
Analysis of: Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
In a phase II trial , Pfizer's Sutent produced an overall response arte of 11 % as second line treatment for patients with non-small cell lung cancer. The response rates is similar to approved agents for recurrent patients with an oral "targeted " drug and favorable safety profile. The role would be...
February 1, 2008
Hematide: A safer ESA??
Analysis of: Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia | www.pipelinereview.com
Author: GLG Expert Contributor
Takeda is collaborating with Effamax to conduct a phase I trial investigating a new erythropoeitin stimulating agent  ( ESA) in anemic patients with refractory solid tumors receiving chemotherapy. The study is well designed and if the new agent has efficacy of Aranesp ( Amgen) and Procrit ( J&...
January 30, 2008
Can Hematiide Replace Aranesp/Procrit for Chemotherapy Induced Anemia?
Analysis of: Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
Anemia represents a common problem in patients treated with chemotherapy.  Although Aranesp and Procrit represented frequently used therapies for the treatment of chemotherapy induced anemia, the recent warnings regarding potential toxicities of these agents limit their use by many physicians. ...
January 30, 2008
Neuropathic Pain: Large Market- Few Good Options
Analysis of: Pipeline Insight: Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market | www.pipelinereview.com
Author: Michael Grossbard, Professor of Clinical Medicine, Columbia University College of Physicians and Surgeons
As I medical oncologist, I frequently deal with neuropathic pain caused either directly by tumors or for complications of cancer therapy.  this is a frequent complaint that impairs quality of life for cancer patients.  Current options for treatment all provides suboptimal efficacy and there...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 Next61 to 70 of 337

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-04T21:45:18.380